Dapagliflozin Plus Liraglutide: Dual Drug Approach to Cardio-Renal Protection
Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enhanced cardio-renal protection through complementary mechanisms.
Quick Facts
What This Study Found
Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enhanced cardio-renal protection through complementary mechanisms.
Key Numbers
30 rats total: 6 controls, 24 diabetic rats split into 4 groups. High-fat diet for 4 weeks followed by single-dose streptozotocin to induce diabetes.
How They Did This
Study design and methodology detailed in the full publication.
Why This Research Matters
These findings have significant implications for peptide-based therapeutic development and clinical practice.
The Bigger Picture
This study contributes to the expanding understanding of how peptide-based therapeutics can be applied across medical specialties.
What This Study Doesn't Tell Us
Study-specific limitations discussed in the full publication. Results should be interpreted within the context of study design.
Questions This Raises
- ?What are the long-term implications?
- ?How do these results compare to existing evidence?
- ?What further research is needed?
Trust & Context
- Key Stat:
- Key finding Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enha
- Evidence Grade:
- Evidence assessment based on study design detailed in publication.
- Study Age:
- Published in 2025. Current peptide therapeutic research.
- Original Title:
- The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats.
- Published In:
- Journal of experimental pharmacology, 17, 467-484 (2025)
- Authors:
- Albanna, Adel Ali, Ibrahim, Doa'a Anwar, Shamsher, Amani Mohammed, Al-Shawia, Mojahed Ali, Halboup, Abdulsalam
- Database ID:
- RPEP-09844
Evidence Hierarchy
Frequently Asked Questions
What does this study mean for patients?
Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enhanced cardio-renal protection through complementary mechanisms.
How reliable are these findings?
Evidence strength depends on study design. Consult the full publication and your healthcare provider for personalized guidance.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09844APA
Albanna, Adel Ali; Ibrahim, Doa'a Anwar; Shamsher, Amani Mohammed; Al-Shawia, Mojahed Ali; Halboup, Abdulsalam. (2025). The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats.. Journal of experimental pharmacology, 17, 467-484. https://doi.org/10.2147/JEP.S522053
MLA
Albanna, Adel Ali, et al. "The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats.." Journal of experimental pharmacology, 2025. https://doi.org/10.2147/JEP.S522053
RethinkPeptides
RethinkPeptides Research Database. "The Potential Effect of Dapagliflozin and Liraglutide in Att..." RPEP-09844. Retrieved from https://rethinkpeptides.com/research/albanna-2025-the-potential-effect-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.